Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to the Medicaid "redetermination" process and that premium rates were sufficient to cover rising costs [4]. - The actual situation revealed that the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) and lowered EPS guidance for 2024 from $37.20 to $33.00 (11.3%), the stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [7][8].

Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contract ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential legal issues related to misleading statements made by the company regarding Medicaid costs and premium rates [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by July 11, 2025 [1][3]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements about their monitoring of cost trends related to the Medicaid redetermination process, which was not accurately reflected in their financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately accounted for, while in reality, the acuity and utilization of Medicaid members were increasing significantly due to the redetermination process [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of misleading statements regarding Medicaid cost trends and financial guidance, which led to significant stock price declines [2][4][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elevance between April 18, 2024, and October 16, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elevance, with a deadline of July 11, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance and its executives violated federal securities laws by making false or misleading statements about their monitoring of Medicaid cost trends and the adequacy of premium rates [4]. - On July 17, 2024, Elevance disclosed an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, or 5.8% [5]. - Further revelations on October 17, 2024, indicated that Elevance missed EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a stock price drop of $52.61 per share, or 10.6% [6]. Group 3: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [7]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding Elevance's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of Indiana on behalf of individuals and entities that purchased Elevance securities between April 18, 2024, and October 16, 2024 [1]. - Investors have until July 11, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Elevance - Defendants allegedly misrepresented their monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - The lawsuit claims that while Medicaid expenses were acknowledged to be rising, the true impact of the redetermination process was not adequately reflected in Elevance's financial guidance for 2024 [3]. - It is asserted that the acuity and utilization of Medicaid members increased significantly, as those removed from Medicaid were generally healthier than those who remained eligible [3]. Impact on Investors - The lawsuit contends that when the true details regarding the Medicaid redetermination process became public, investors suffered damages due to the misleading statements made by Elevance [3].

Core Viewpoint - UnitedHealth Group is currently facing significant challenges, including a criminal investigation into potential Medicare fraud, disappointing financial performance, and leadership changes, which have led to a substantial decline in stock value [1][2][5][14]. Financial Performance - In the first quarter, UnitedHealth missed both earnings and revenue estimates, with earnings projected to decline by 4.7% for 2025, despite a revenue increase of 13.1% year over year [2][6]. - The company generated $5.5 billion in operating cash flow in the first quarter, a significant increase from $1.1 billion the previous year, and ended the quarter with $34.3 billion in cash and short-term investments [13]. Stock Performance - UnitedHealth's shares have dropped 21.2% over the past week, resulting in a year-to-date decline of 39.1%, underperforming the industry and the S&P 500 [2][5]. - The stock currently trades at a forward P/E of 11.16X, which is above the industry average of 10.87X, indicating a premium valuation despite the recent selloff [8]. Leadership Changes - The company has experienced a leadership shake-up, with former CEO Andrew Witty stepping down and Stephen Hemsley returning to lead the company [2][10]. Regulatory and Legal Issues - The Department of Justice is investigating UnitedHealth for potential Medicare fraud, a probe that reportedly began last summer, following a previous inquiry into its Medicare billing practices [5][14]. - The company has faced scrutiny from a cyberattack in 2024, resulting in a data breach and federal investigation, along with other legal challenges [4][5]. Market Position and Future Outlook - Despite recent setbacks, UnitedHealth maintains a strong market position, serving 50.1 million people as of March 31, 2025, and is well-positioned to benefit from long-term industry trends due to rising healthcare spending [12]. - Potential tailwinds include projected Medicare Advantage rate hikes for 2026 and investments in AI and digital health tools aimed at improving efficiency and consumer experience [11][12].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations Against Elevance - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Performance and Financial Impact - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding Medicaid cost trends and premium negotiations [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance Health common stock between April 18, 2024, and October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, while in reality, the acuity and utilization of Medicaid members were increasing significantly [5]. - The lawsuit suggests that the members being removed from Medicaid were healthier than those who remained, which was not accounted for in Elevance's rate negotiations or financial forecasts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for alleged violations of federal securities laws during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Elevance misrepresented its monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - It is alleged that while Elevance acknowledged rising Medicaid expenses, the company misled investors by stating that these costs were adequately reflected in its financial guidance for 2024 [3]. - The complaint highlights that the redetermination process led to a significant increase in the acuity and utilization of Medicaid members, contradicting Elevance's representations regarding its financial outlook [3]. Group 2: Investor Participation - Investors who purchased Elevance securities during the Class Period are encouraged to join the lawsuit, with a deadline of July 11, 2025, to request lead plaintiff status [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Group 1 - The US stock market has turned positive for the year, driven by a rebound led by tech giants amid easing inflation and a pause in the global trade war [1][3] - The S&P 500 index rose 0.7% and the Nasdaq 100 index surged 1.6%, with both indices achieving positive cumulative gains for 2025 [1] - The "seven giants" including Nvidia, Apple, and Meta saw an 8% increase this week, marking the largest two-day gain since early April [1] Group 2 - The release of the US April CPI data, which was lower than expected, ignited market optimism, leading to full pricing of a potential Fed rate cut in September [1] - JPMorgan has lifted its US economic growth forecast and removed recession warnings following the improved inflation data [1] - The semiconductor sector performed strongly, with Nvidia announcing a partnership with AMD for a project in Saudi Arabia, resulting in a 3% rise in the Philadelphia Semiconductor Index [3] Group 3 - UnitedHealth's stock plummeted 18% after a sudden leadership change, dragging down the healthcare sector within the S&P 500 [4] - The company suspended its full-year earnings guidance due to higher-than-expected medical spending, affecting peers like Elevance Health and CVS [4] Group 4 - Hertz faced its largest single-day drop in over a year, with a 17% decline due to worse-than-expected first-quarter losses [6] - 3D Systems' stock fell 27% after reporting first-quarter product revenue below analyst expectations [6] - First Solar's stock surged 23% following a favorable tax proposal for the solar industry, while Plug Power dropped 10% due to a proposal to eliminate hydrogen production tax credits [6]